InSilicoTrials Highlighted in HSBC Venture Healthcare Report for 1H 2024
The HSBC Healthcare Annual Report for the first half of 2024 provides an extensive analysis of the healthcare sector, focusing on trends in venture capital investments, biopharma, medical devices, and health tech. This report, authored by HSBC Innovation Banking, serves … Read More
FDA DRAFT GUIDANCE: Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies Guidance for Industry
In recent years, the US Congress and the US Food and Drug Administration (FDA) have emphasized the importance of including underrepresented populations in clinical trials. This push for diversity is not just a regulatory requirement but a critical step towards … Read More
Charting New Horizons for Clinical Trials: InSilicoTrials at DIA 2024
InSilicoTrials recently participated in the DIA 2024 Global Annual Meeting, (16-20 June, San Diego), sharing valuable insights on the use of in silico trials, digital twins, and AI-powered predictive intelligence in drug development and patient care. This event provided a … Read More
In Silico Technologies: A Strategic Imperative for Accelerating Breakthroughs and Market Leadership for FDA-Regulated Products
InSilicoTrials recently collaborated with a team of experts led by Tina M. Morrison on a significant initiative supported by the FDA and the U.S. Department of Health and Human Services. The project, titled “A Strategic Imperative for Accelerating Breakthroughs and … Read More
Living with Amyotrophic Lateral Sclerosis
Theย BRAINTEASER Community of Practice Second webinar Advances in digital technology are helping us to predict the onset of a disease, how it will progress, or which is the best treatment option for a particular person. In other words, technology … Read More
Axoltis Pharma receives authorization to launch SEALS – phase II clinical trial for ALS patients with drug candidate NX210c
InSilicoTrials partners with Axoltis Pharma to leverage advanced modeling technology, generating predictive analyses of disease progression in virtual subjects based on the baseline characteristics of actual enrolled patients. This collaboration will enhance the development of Axoltisโs NX210c by accelerating the … Read More
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
InSilicoTrials collaborates with Telomir Pharmaceuticals, applying cutting-edge AI and simulation technologies to optimize the development of Telomir-1, a promising agent in the battle against age-related conditions, by improving its safety profile and reducing development costs. BALTIMORE, March 07, 2024 (GLOBE … Read More
Revolutionizing Healthcare: The Emergence and Impact of Synthetic Data in Life Sciences
The realm of healthcare and life sciences is undergoing a transformative shift, fueled by the advent and integration of data-driven technologies. At the forefront of this revolution is the burgeoning use of synthetic data, a groundbreaking development poised to redefine … Read More
Women in Multiple Sclerosis webinar: take-home messages
In the Webinar: Women in Multiple Sclerosis, hosted by the Community of Practice of the BRAINTEASER project, we focused on the role of hormones on the onset and progression of the disease and delved deeply into several aspects of pregnancy. … Read More
The book ๐ง๐ผ๐๐ฎ๐ฟ๐ฑ ๐๐ผ๐ผ๐ฑ ๐ฆ๐ถ๐บ๐๐น๐ฎ๐๐ถ๐ผ๐ป ๐ฃ๐ฟ๐ฎ๐ฐ๐๐ถ๐ฐ๐ฒ Published Open Access on Springer Nature
InSilicoTrials is thrilled to announce the publication of “๐๐ค๐ฌ๐๐ง๐ ๐๐ค๐คd ๐๐๐ข๐ช๐ก๐๐ฉ๐๐ค๐ฃ ๐๐ง๐๐๐ฉ๐๐๐ – Best practices for the use of computational modelling & simulation in the regulatory process of biomedical products ” a crucial document guiding the use of simulation data … Read More